Predictive Biosciences Features Novel Multiplex PCR Assay for FGFR3 Mutation Detection at the ASCO 2011 Genitourinary Cancers Symposium

Back To Press & Events


LEXINGTON, MA – February 18, 2011 – Predictive Biosciences today announced that the Company will be presenting results on the development of a real-time multiplexed PCR assay for detection of FGFR3 mutations in urine and tissue at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17 – 19 in Orlando, Florida. Results will also focus on the application of the assay which is currently being used in Predictive’s first commercial molecular grading product, the CertNDxTM Molecular Grading Assay.

Predictive will highlight the improved and more efficient data analysis that the unique multiplex FGFR3 assay provides during the General Poster Session C: Penile, Urethral, Bladder and Testicular Cancers on Friday February 18, 2011 from 12:30 p.m. to 1:45 p.m. (EST) and again from 5:00 p.m. to 6:15 p.m (EST).

Abstract Number: 271
Poster Title: “Development of a real-time multiplex PCR assay for the detection of FGFR3 mutations in urine”
Lead Author: John Millholland
Poster Number: A73

Following the symposium, the poster will be available in the Posters and Abstracts section of the Predictive Biosciences website at:  

Share On Twitter Linkedin